MRK
$115.43
Merck & Co., Inc.
Recent News
Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?
MRK bets on new products and a growing pipeline as Keytruda nears 2028 LOE, with $70B potential commercial opportunities projected by mid-2030s.
This Schwab ETF Holds 100 Dividend Stocks, Charges $6 a Year, and Yields More Than Most Savings Accounts
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) costs $6 a year on a $10,000 investment, holds 100 dividend stocks, and currently yields 3.39%. With the Fed funds rate sitting at 3.75% and most high-yield savings accounts paying in that same neighborhood, the yield gap is narrow. But SCHD adds something a savings account never will: price ... This Schwab ETF Holds 100 Dividend Stocks, Charges $6 a Year, and Yields More Than Most Savings Accounts
Here’s Why Merck (MRK) Surged in Q4
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Value Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in undervalued companies with strong financial condition and attractive business economics. US equities ended a record year with robust fourth-quarter gains. AI remains the main […]
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink
Exelixis (NASDAQ:EXEL) executives and investors spent part of the discussion at a Leerink event focusing on recent renal cell carcinoma (RCC) data, evolving treatment sequencing debates, and the company’s late-stage pipeline plans around its next-generation tyrosine kinase inhibitor (TKI) zanzalinti
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference
Exelixis (NASDAQ:EXEL) detailed its commercial momentum for cabozantinib and outlined key upcoming clinical catalysts for zanzalintinib during a discussion at the Citizens Life Sciences Conference featuring Andrew Peters. Cabozantinib performance and 2026 outlook Peters said 2025 was “an exciting y